Amyloid‐beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years
Open accessAbstract
Introduction: Blood‐based biomarkers for Alzheimer's disease (AD) are urgently needed. Here, four plasma biomarkers were measured at baseline in a community‐based cohort followed over 17 years, and the association with clinical AD risk was determined. Methods: Amyloid beta (Aβ) misfolding status as a structure‐based biomarker as well as phosphorylated tau 181 (P‐tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) concentration levels were determined at baseline in heparin plasma from 68 participants who were diagnosed with AD and 240 controls without dementia diagnosis throughout follow‐up. Results: Aβ misfolding exhibited high disease prediction accuracy of AD diagnosis within 17 years. Among the concentration markers, GFAP showed the best performance, followed by NfL and P‐tau181. The combination of Aβ misfolding and GFAP increased the accuracy. Discussion: Aβ misfolding and GFAP showed a strong ability to predict clinical AD risk and may be important early AD risk markers. Aβ misfolding illustrated its potential as a prescreening tool for AD risk stratification in older adults.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Blood biomarkers of amyloid-β misfolding have shown promise in predicting future AD dementia.
“Blood biomarkers of amyloid-β misfolding have shown promise in this regard60,61.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [60]
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · see citing works
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
Janelidze, S., Teunissen, C. E., Zetterberg, H., Allué, J. A., Sarasa, L., Eichenlaub, U., Bittner, T., Ovod, V., Verberk, I. M. W., Toba, K., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3180 · Cited by 494 · see citing works
The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease
Hadjichrysanthou, C., Evans, S., Bajaj, S., Siakallis, L. C., McRae-McKee, K., de Wolf, F., Anderson, R. M., & Initiative, T. A. D. N. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00636-z · Cited by 86 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Kim, K. Y., Shin, K. Y., & Chang, K.-A. (2023) · Cells · doi:10.3390/cells12091309 · Cited by 309 · see citing works
Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability
Therriault, J., Janelidze, S., Benedet, A. L., Ashton, N. J., Arranz Martínez, J., Gonzalez-Escalante, A., Bellaver, B., Alcolea, D., Vrillon, A., Karim, H., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00731-y · Cited by 112 · see citing works
“Blood biomarkers of amyloid-β misfolding have shown promise in this regard 60,61 .”
Lista, S., Imbimbo, B. P., Grasso, M., Fidilio, A., Emanuele, E., Minoretti, P., López-Ortiz, S., Martín-Hernández, J., Gabelle, A., Caruso, G., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03163-y · Cited by 81 · see citing works
Plasma ATN(I) classification and precision pharmacology in Alzheimer's disease
Imbimbo, B. P., Watling, M., Imbimbo, C., & Nisticò, R. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13084 · Cited by 34 · see citing works
- Authors
- Beyer, L., Stocker, H., Rujescu, D., Holleczek, B., Stockmann, J., Nabers, A., Brenner, H., & Gerwert, K.
- Affiliations
- Ruhr University Bochum (DE)
- German Cancer Research Center (DE)
- Medical University of Vienna (AT)
- Krebsregister Saarland (DE)
- Corresponding author
- Gerwert, Klaus
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2022-07-19
- Volume
- 19
- Issue
- 3
- Pages
- 1020-1028
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W4285796777
- Cited by
- 81
- References
- 3
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 23 · 2023: 17 · 2022: 4
- FWCI
- 10.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Glial Fibrillary Acidic Protein, Humans, Male, Middle Aged, Phosphorylation, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Neurofilament Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
